S

Sanofi

Global pharma company; vaccines and R&D

Head of GTMC

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
No salary listed
Expert
Bachelor's
Taipei City, Taiwan
In PersonThe role supports Hong Kong and Taiwan markets; ATS workplace is Taipei, Taiwan.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree in Business, Marketing, or a related field is required.
  • At least 10 years of relevant professional business experience is required, preferably in omnichannel operational marketing within healthcare, FMCG, or a relevant industry.
  • Ability to work cross-functionally is required.
  • Strong strategic marketing, analytical, and planning skills are required.
  • Fluency in spoken and written English is required; Mandarin is welcomed.
  • An inspiring leadership style with demonstrated ability to lead and motivate a diverse team is required.
  • Ability to execute, work comfortably with ambiguity, and adapt with agility is required.
  • Strategic thinking that challenges the status quo through innovation while remaining pragmatic and focused on priorities is required.
  • Ability to drive action across the team and with stakeholders is required.
Responsibilities
  • Ensure the successful transition and build-up phase for the new GTMC team in Hong Kong and Taiwan, aligned with the global GTMC strategy and objectives, and implement standardized approaches that support business growth.
  • Define and establish the Hong Kong and Taiwan GTMC team by integrating existing capabilities and resources and building or enriching new capabilities.
  • Drive restructuring, refinement, and streamlining of existing activities synergistically across business units.
  • Support centralization of key go-to-market capabilities at scale in Sanofi Global Hubs, including successful transfer of selected activities and integration with advanced digital technology.
  • Promote innovative ways of working through lean and effective GTMC governance for the Greater China team and clearly delineate interfaces with key functions such as Digital and hubs.
  • Create and implement a Hong Kong and Taiwan GTMC strategy that incorporates local demands and aligns with the global GTMC strategy and objectives to enhance local commercial capabilities, particularly by fostering new cross-GBU programs that maximize value for One Sanofi.
  • Establish a GTMC team that drives growth through targeted insights and analytics, increases globalization and standardization across GBUs, and leverages Global Hubs where helpful to increase efficiency while understanding the needs and nuances of each GBU.
  • Support impactful customer experiences for healthcare professionals and patients through integrated engagements and solutions that are consistent, seamless, and scalable to different market requirements, using best-in-class methodology across GBUs.
  • Drive development and implementation of a global launch excellence framework and capabilities to ensure a holistic, best-in-class approach to product launches.
  • Oversee the creation of omnichannel solutions suited to the needs of various GBUs and help brands and franchises optimize customer approaches by fully leveraging system capabilities.
  • Contribute to continuous effectiveness, drive change, and support upskilling.
  • Set and communicate strategic priorities for GTMC pillars aligned with global GTMC priorities, ensuring objectives connect with Hong Kong and Taiwan business priorities.
  • Oversee resource and budget planning within GTMC in alignment with local GBUs.
  • Serve as a member of the Hong Kong and Taiwan Commercial Leadership Team and work closely with business units to support business needs and enable go-to-market operations and transformation.
  • Serve as a member of the Greater China GTMC Leadership Team and work with global GTMC pillar heads.
  • Foster partnerships and close collaboration among GBU, GTMC, Hubs, and Digital teams, and institutionalize ways of working to provide maximum value and efficiency to business teams.
  • Foster collaboration with China and other markets to ensure consistency across markets and share best practices and learnings.
  • Build and develop a team that leverages complementary strengths and develop dedicated, strong, and diverse talent through a One Sanofi mindset.
Desired Qualifications
  • Experience working in or with global GTMC teams is preferred.
  • Commercial Operations knowledge and understanding of key dimensions such as Insight and Analytics, Field Operations, Omnichannel, and Marketing Operations is a plus.
  • Experience in omnichannel operational marketing in healthcare, FMCG, or a relevant industry is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...